Released : Jun 25, 2014

25 June 2014

TIZIANA LIFE SCIENCES PLC (the "Company")
Result of Annual General Meeting

At the Annual General Meeting of the Company held earlier today all resolutions were duly passed.

Gabriele Cerrone made the following statement:

"To date, 2014 has been an exciting year for Tiziana Life Sciences PLC. The successful completion of its AIM listing in April, via a reverse takeover, and the associated fundraising, has put the Company in a strong position to advance its promising Bcl-3 lead programme towards Phase I clinical trials. Furthermore, in June the Company further strengthened its balance sheet with the issue of £1,451,472 convertible loan notes.

"I have been particularly pleased to welcome Dr Napoleone Ferrara, a scientist whose achievements have done so much to advance the treatment of cancer, as Chairman of the Company's new Scientific Advisory Board and as a consultant to the Company. I now look forward to continuing to build on the excellent progress we have made over the last year."

Contacts:

Tiziana Life Sciences PLC Philip Boyd	+44 (0)20 7493 2853
Cairn Financial Advisers LLP - Nominated Adviser Liam Murray / Avi Robinson	+44 (0)20 7148 7900
Beaufort Securities Limited - Broker Saif Janjua	+44 (0)20 7382 8300
FTI Consulting Limited John Dineen	+44 (0)20 3727 1136

About Tiziana Life Sciences
Tiziana Life Sciences is a UK biotechnology company whose mission is to discover and develop novel molecules that impact human disease in the area of oncology, with a particular focus on metastatic cancers.

For more information go to http://www.tizianalifesciences.com

 

---

 

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Tiziana Life Sciences PLC via Globenewswire

HUG#1802570